Patients continuing treatment Patients continuing treatment Patients discontinuing treatment Total
Number of patients (%) Number of patients (%) Number of patients (%) Number of patients (%) Number of patients (%) Number of patients (%) 1580 (86.3%) 1580 (86.3%) 251 (13.7%) 1831
Age [years] (±SD) Age [years] (±SD) Age [years] (±SD) Age [years] (±SD) Age [years] (±SD) Age [years] (±SD) 42.3 (17.2) 42.3 (17.2) 41.5 (18.2) 42.2 (17.4)
Gender [Males] n pts (%) Gender [Males] n pts (%) Gender [Males] n pts (%) Gender [Males] n pts (%) Gender [Males] n pts (%) Gender [Males] n pts (%) 867 (54.9%) 867 (54.9%) 132 (52.6%) 999 (54.6%)
Smoking Smoking Smoking No No No 1087 (68.9%) 1087 (68.9%) 172 (68.5%) 1259 (68.8%)
Yes Yes Yes 365 (23.1%) 365 (23.1%) 59 (23.5%) 424 (23.2%)
Former smoker Former smoker Former smoker 126 (8.0%) 126 (8.0%) 20 (8.0%) 146 (8.0%)
Concomitant atopic conditions Concomitant atopic conditions Concomitant atopic conditions Rhinitis Rhinitis Rhinitis 741 (46.9%) 741 (46.9%) 118 (47.0%) 859 (46.9%)
Conjunctivitis Conjunctivitis Conjunctivitis 563 (35.7%) 563 (35.7%) 77 (30.8%) 640 (35.0%)
Asthma Asthma Asthma 498 (31.5%) 498 (31.5%) 79 (31.5%) 577 (31.5%)
Total of treatment course interruptions Total of treatment course interruptions Total of treatment course interruptions - - 286 286
Timepoint 1 (lockdown- phase 1)
Stopped Therapy
By patient decision
By patient decision
By patient decision
-
-
92/286 (32.2%)
92/286 (32.2%)
92
By dermatologist By dermatologist By dermatologist - - 41/286 (14.3%) 41/286 (14.3%) 41
By general practitioner By general practitioner By general practitioner - - 12/286 (4.2%) 12/286 (4.2%) 12
Unknown Unknown Unknown - - 47/286 (16.4%) 47/286 (16.4%) 141
Reason for stopping therapy Any reason Any reason Any reason 192/286 (67.1%) 192/286 (67.1%)
Fear of SARS-CoV-2 infection Fear of SARS-CoV-2 infection Fear of SARS-CoV-2 infection - - 62/286 (21.7) 62/286 (21.7) 62
SARS-CoV-2 infection SARS-CoV-2 infection SARS-CoV-2 infection - - 6/286 (2.1%) 6/286 (2.1%) 6
Contact with SARS-CoV-2+ subject Contact with SARS-CoV-2+ subject Contact with SARS-CoV-2+ subject - - 7/286 (2.4%) 7/286 (2.4%) 7
Comorbidity Comorbidity Comorbidity - - 10/286 (3.5%) 10/286 (3.5%) 10
Age > 60 years old Age > 60 years old Age > 60 years old - - 6/286 (2.1%) 6/286 (2.1%) 6
Other (i.e., drug supply, no mobility, etc) Other (i.e., drug supply, no mobility, etc) Other (i.e., drug supply, no mobility, etc) - - 101/286 (35.3%) 101/286 (35.3%) 101
Timepoint 2 (phase 2)
Stopped Therapy
By patient decision
By patient decision
By patient decision
-
-
14/286 (4.9%)
14/286 (4.9%)
14
By dermatologist By dermatologist By dermatologist - - 22/286 (8.5%) 22/286 (8.5%) 22
By general practitioner By general practitioner By general practitioner - - 3/286 (6.0%) 3/286 (6.0%) 3
Unknown Unknown Unknown - - 9/286 (1.0%) 9/286 (1.0%) 9
Reason for stopping therapy Any reason Any reason Any reason - - 48/286 (16.8% ) 48/286 (16.8% ) 48
Fear of SARS-CoV-2 infection Fear of SARS-CoV-2 infection Fear of SARS-CoV-2 infection - - 6/286 (2.1%) 6/286 (2.1%) 6
SARS-CoV-2 infection SARS-CoV-2 infection SARS-CoV-2 infection - - 2/286 (0.7%) 2/286 (0.7%) 2
Contact with SARS-CoV-2+ subject Contact with SARS-CoV-2+ subject Contact with SARS-CoV-2+ subject - - - - -
Comorbidity Comorbidity Comorbidity - - 5/286 (1.7%) 5/286 (1.7%) 5
Age > 60 years old Age > 60 years old Age > 60 years old - - 3/286 (1%) 3/286 (1%) 3
Other (i.e., drug supply, no mobility, etc) Other (i.e., drug supply, no mobility, etc) Other (i.e., drug supply, no mobility, etc) - - 32/286 (11.2%) 32/286 (11.2%) 32
Timepoint 3 (phase 3)
Stopped Therapy
By patient decision
By patient decision
By patient decision
-
-
8/286 (2.8%)
8/286 (2.8%)
8
By dermatologist By dermatologist By dermatologist - - 23/286 (8.0%) 23/286 (8.0%) 23
By general practitioner By general practitioner By general practitioner - - 1/286 (2.1%) 1/286 (2.1%) 1
Unknown Unknown Unknown - - 14/286 (30.4%) 14/286 (30.4%) 14
Reason for stopping therapy Any reason Any reason Any reason - - 46/286 (16.1%) 46/286 (16.1%) 46
Fear of SARS-CoV-2 infection Fear of SARS-CoV-2 infection Fear of SARS-CoV-2 infection - - 3/286 (1.0%) 3/286 (1.0%) 3
SARS-CoV-2 infection SARS-CoV-2 infection SARS-CoV-2 infection - - - - -
Contact with SARS-CoV-2+ subject Contact with SARS-CoV-2+ subject Contact with SARS-CoV-2+ subject - - - - -
Comorbidity Comorbidity Comorbidity - - 2/286 (0.7%) 2/286 (0.7%) 2
Age > 60 years old Age > 60 years old Age > 60 years old - - 6/286 (2.1%) 6/286 (2.1%) 6
Other (i.e., drug supply, no mobility) Other (i.e., drug supply, no mobility) Other (i.e., drug supply, no mobility) - - 35/286 (12.2%) 35/286 (12.2%) 35
Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption Missing data about decision of treatment interruption 70/286 (24.5%)
Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) Number of patients lost to follow up (%) 142/1831 (7.7%)